Lines of investigation
Research lines of our laboratory are focused on the identification of genes and proteins implicated in the occurrence and development of psychiatric (anxiety, depression, substance use, post-traumatic stress, etc.) and neurological (Parkinson´s disease, Alzheimer´s disease, etc.) disorders, which can be relevant for the discovery of new therapeutic targets to improve its pharmacological management.
For that purpose, we employ validated animal models of the psychiatric and neurological disorders that we want to study. These animal models must be able to reproduce, at least in part, certain behavioural traits and/or neurobiological features of the illnesses that they are simulating. Thus, the objective is to enhance the translational capacity of animal modelization that allows for applying the results to the patient.
The improvement of our knowledge about the alterations implicated in the aetiology and the development of different psychiatric and neurological disorders is one of our main goals, closely related with the discovery of more effective and safer pharmacological approaches. In the last years, we are focused on the role of the endocannabinoid system in the regulation of different brain functions and its potential pharmacotherapeutic exploitation. To this aim, we are very interested in the behavioural and neurochemical effects of genetic or pharmacological manipulation of the endocannabinoid system, employing transgenic animal models or cannabinoid compounds, respectively.
In our studies, we design and perform experiments to evaluate behavioral features related with emotional (anxiety, depression, stress, etc.) and cognitive (prepulse inhibition, memory impairment, etc.) alterations, and with the reinforcing and motivational effects of drugs of abuse (alcohol, cocaine, etc.). Furthermore, to evaluate the neurochemical changes that could be related with behaviour, we analyse gene expression of key targets by real time PCR or in situ hybridization experiments, as well as protein expression by immunohistochemistry or Western Blot techniques.
Laboratory members have a long-lasting and continuous relationship with several groups of psychiatrists and neurologists. This fact has significantly contributed to establish a reciprocal bridge of information between preclinical and clinical research, which has been reflected in several joint publications. Our objective is to maintain and to strengthen this type of collaborative strategies aimed to encourage translational research and finally improve the quality of life of psychiatric and neurological patients.
Representative Publications
- A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders. María S. García-Gutiérrez , Abraham B. Torregrosa, Francisco Navarrete, Daniela Navarro , Jorge Manzanares Pharmacological Research. 2025 213: 107657 https://doi.org/10.1016/j.phrs.2025.107657
- Changes in neurobiological markers of reactivity to alcohol-related stimuli in alcohol-dependent patients after two years of treatment. Gabriel Rubio, Marta Marín, Cristina Martín-Arriscado Arroba, Enrique Rubio-Escobar, Francisco Arias, Abraham B. Torregrosa, Jorge Manzanares. Front. Psychiatry. 2025 Volume 16 - Sec. Addictive Disorders https://doi.org/10.3389/fpsyt.2025.1613169
- Editorial: Methylation in the human brain. Sheila T. Nagamatsu, Francisco Navarrete, Maria S. Garcia-Gutierrez. Front. Genet. 2025 Sec. Behavioral and Psychiatric Genetics; Volume 16 https://doi.org/10.3389/fgene.2025.1589816
- ESTraS, an easy and simple tracking system for assessing rodent behavior. A. Morcuende, T. Femenía, J. Manzanares & A. Gasparyan. Behav Res. 2025 57; article number 90 https://doi.org/10.3758/s13428-024-02537-7
- Whole transcriptome analysis of peripheral blood mononuclear cells from de novo and drug-naïve Parkinson’s disease patients. Navarrete F, Guillot-Fernández M, Martínez-Hostyn L, Navarro D, Molina J A, López-Atalaya J P and Manzanares J. Neurotherapeutics. 2025 e00762 https://doi.org/10.1016/j.neurot.2025.e00762
- Additive antinociceptive action of intrathecal anandamide reuptake inhibitor and morphine in the management of post-incisional pain in rats. Antonio J. Carrascosa, María S. García-Gutiérrez, Raquel Saldaña, Jorge Manzanares. Biomedicine & Pharmacotherapy. 2024 177: 117054 https://doi.org/10.1016/j.biopha.2024.117054
- Adolescent intermittent ethanol exposure decreases perineuronal nets in the hippocampus in a sex dependent manner: Modulation through pharmacological inhibition of RPTPβ/ζ. Milagros Galán-Llario , Esther Gramage, Alba García-Guerra, Abraham B. Torregrosa , Ani Gasparyan , Daniela Navarro , Francisco Navarrete , María Salud García-Gutiérrez , Jorge Manzanares, Gonzalo Herradón Neuropharmacology. 2024 247: 109850 https://doi.org/10.1016/j.neuropharm.2024.109850
- Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality. Antonio J Carrascosa, Francisco Navarrete , Raquel Saldaña María S García-Gutiérrez, Belinda Montalbán , Daniela Navarro, Fernando M Gómez-Guijarro, Ani Gasparyan, Elena Murcia-Sánchez , Abraham B Torregrosa, Paloma Pérez-Doblado, Luisa Gutiérrez, Jorge Manzanares. Int J Mol Sci. 2024 25(11): 6268 https://doi.org/10.3390/ijms25116268
- Fetal Cannabinoid Syndrome: Behavioral and Brain Alterations of the Offspring Exposed to Dronabinol during Gestation and Lactation. Daniela Navarro, Ani Gasparyan, Francisco Navarrete and Jorge Manzanares. Int. J. Mol. Sci. 2024 25(13), 7453 https://doi.org/10.3390/ijms25137453
- Cannabidiol repairs brain damage and behavioral alterations in mice with fetal alcohol spectrum Ani Gasparyan, Daniela Navarro, Francisco Navarrete, Amaya Austrich-Olivares, Ernest R.Scoma, Vedangi D.Hambardikar, Gabriela B. Acosta, María E.Solesio, Jorge Manzanares Pharmacological Research 2023 Volume 188, February 2023, 106655 https://doi.org/10.1016/j.phrs.2023.106655
Español